660
Participants
Start Date
November 28, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
April 30, 2026
SHAPE measurement (Sonazoid ultrasoud contrast agent)
Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
SHAPE measurement (Definity ultrasoud contrast agent)
Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
RECRUITING
University of Bern, Bern
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Thomas Jefferson University, Dept of Radiology, Philadelphia
University of Pennsylvania
OTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Bern
OTHER
Thomas Jefferson University
OTHER